After rapid integration of NIH-funded Librede technology, company now focused on scaling to commercial quantities and launching new consumer products
BERKELEY, Calif.–(BUSINESS WIRE)–Lygos, Inc., a full-stack provider of sustainable specialty ingredients that deliver high-value performance without environmental toxicity, has announced the successful validation of a novel cannabinoid production pathway using its proprietary fermentation and processing technology. A direct result of the recent Librede acquisition and integration of additional Lygos technology advances, the new fermentation process enables the production of any cannabinoid and cannabinoid-based product of interest in an environmentally safe, sustainable and cost-effective manner at industrial scale (>100 kg) for numerous consumer markets.
Librede, a wholly owned subsidiary of Lygos, had primarily operated on grants from the National Institutes of Health (NIH) prior to the Lygos acquisition. The company’s technology was designed for the low-cost production of a wide range of valuable cannabinoid compounds that are not easily accessible through traditional agricultural means. The platform supports both ultra-rare and common cannabinoids, such as CBD, that feature compelling performance, economic and environmental advantages over traditional plant-based alternatives.
“Librede’s vision was to create a production platform for any cannabinoid at costs to drive widespread consumer access,” said Jason Poulos, PhD, CEO of Librede. “To advance this vision, we needed the ability to access any compound, scale our technology to levels that support consumer product manufacturing, and form key marketing relationships for existing and emerging markets. We have achieved the first of these objectives, have definitive plans for the second, and are working diligently on the third. We are now very close to advancing the platform to provide direct benefit to consumers.”
“We couldn’t be more pleased at the speed with which the Librede and Lygos teams integrated efforts and technologies despite the global pandemic and shutdowns. These rapid advances have accelerated our timetable for forming partnerships and delivering new cannabinoid-enabled products into the market,” said Eric Steen, PhD, CEO of Lygos. “By delivering high quality, pure and sustainable cannabinoids at commercial volumes and competitive prices, we are poised to rapidly enter high-growth consumer market segments with Lygos branded or co-branded products by capitalizing on the expertise and reach of our strategic partners.”
Lygos has created a full-stack biological engineering platform focused on organic acid specialty ingredients, health & wellness ingredients, including cannabinoids and bio-monomers. Lygos’ sustainable, bio-based chemicals replace expensive, environmentally degrading alternatives from traditional industrial suppliers, enabling customers to create better, safer products with value-added performance. For more information, visit www.lygos.com and follow us @LygosBiotech.
Librede is a wholly owned subsidiary of Lygos that focuses on the production of high-value natural products. Librede’s proprietary biochemistry platform allows for the production of natural compounds, particularly cannabinoids, in a highly efficient and sustainable manner. More information can be found at www.librede.com.
Lygos, Librede and the Lygos logo are trademarks of Lygos, Inc. Any other brands may be trademarks of their respective holders.